The emergency management of ischemic stroke (AIS) and a myocardial infarction (AMI) is based nowadays on comparable methods sharing the endovascular approach. Imaging plays a pivotal role in therapeutic management by enabling assessment of cardiac or brain viability after an ischemic insult and specifying the individual prognosis. In particular, it may assess "reperfusion injury" damage, a potential target for new protective therapies. Unfortunately, clinical reality suffers from the lack of robustness and prohibitive computation time of image acquisition and processing technologies. Thus, an "Optimized Magnetic Resonance Imaging" could allow a more accurate diagnosis and quantification of prognostic markers that are crucial to better select patients likely to benefit from reperfusion and targeted protective therapies.
The MARVELOUS project gathers the academic expertise of basic researchers in the field of ischemia-reperfusion injury, cardiologists, vascular neurologists, radiologists health economists with the private companies Cynbiose (company involved in experimental models development) and Olea Medical (specialized in the development of post-processing systems in medical imaging).
The MARVELOUS program has already enabled the validation of a unique experimental model of brain ischemia-reperfusion in non-human primates (Cynbiose). More than 700 patients were recruited in two cohorts of STEMI and STROKE patients. These prospective and well-designed cohorts have led to major publications highlighting the predictive value of biomarkers in outcome. Collaboration with OLEA Medical has improved the performance of the heart and brain image post-processing software thus allowing a better assessment of post-ischemic damage.